Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Sjoerd A.M.E.G. Timmermans et al.|The Lancet Rheumatology|2020Cited by 199
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialAlexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al.|The Lancet Respiratory Medicine|2022Cited by 143